Identifying novel biomarkers associated with bladder cancer treatment outcomes

Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-03, Vol.13, p.1114203
Main Authors: Castaneda, Peris R, Theodorescu, Dan, Rosser, Charles J, Ahdoot, Michael
Format: Article
Language:English
Subjects:
biomarker
bladder cancer
genetic testing
Oncology
targeted therapy
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3
cites cdi_FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3
container_end_page
container_issue
container_start_page 1114203
container_title Frontiers in oncology
container_volume 13
creator Castaneda, Peris R
Theodorescu, Dan
Rosser, Charles J
Ahdoot, Michael
description Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms "biomarker," "bladder cancer," and the respective treatment discussed (i.e., "neoadjuvant" or "BCG"). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.
doi_str_mv 10.3389/fonc.2023.1114203
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_746f7b6388b4401581657b073d1774c7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_746f7b6388b4401581657b073d1774c7</doaj_id><sourcerecordid>2802428367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3</originalsourceid><addsrcrecordid>eNpVkctuFDEQRS0EIlHIB7BBvWQzQ_nRtnuFUARkpAg2ILGz_ChPHLrbwfYE5e_pyQxR4k1ZVXXPLekS8pbCmnM9fIh59msGjK8ppYIBf0FOGeNiNQj-6-WT_wk5r_UGlid7oMBfkxOuQAoK7JR82wScW4r3ad52c77DsXMpT7b8xlI7W2v2yTYM3d_Urjs32hCwdN7OfimtoG3Tou_yrvk8YX1DXkU7Vjw_1jPy88vnHxeXq6vvXzcXn65WXkjZVoOkvbVBhUGB4zowxyVEiiBA91F56kPgMnjsdeTog2OROmaBoudeUeRnZHPghmxvzG1Jy8X3JttkHhq5bI0tLfkRjRIyKie51k4IoL2mslcOFA9UKeHVwvp4YN3u3ISL6dyKHZ9Bn0_mdG22-c5QgAGEEAvh_ZFQ8p8d1mamVD2Oo50x76phGphgmsu9GT2s-pJrLRgffSiYfa5mn6vZ52qOuS6ad08PfFT8T5H_A1TSoCk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2802428367</pqid></control><display><type>article</type><title>Identifying novel biomarkers associated with bladder cancer treatment outcomes</title><source>PubMed Central Free</source><creator>Castaneda, Peris R ; Theodorescu, Dan ; Rosser, Charles J ; Ahdoot, Michael</creator><creatorcontrib>Castaneda, Peris R ; Theodorescu, Dan ; Rosser, Charles J ; Ahdoot, Michael</creatorcontrib><description>Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms "biomarker," "bladder cancer," and the respective treatment discussed (i.e., "neoadjuvant" or "BCG"). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2023.1114203</identifier><identifier>PMID: 37064102</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>biomarker ; bladder cancer ; genetic testing ; Oncology ; targeted therapy ; treatment</subject><ispartof>Frontiers in oncology, 2023-03, Vol.13, p.1114203</ispartof><rights>Copyright © 2023 Castaneda, Theodorescu, Rosser and Ahdoot.</rights><rights>Copyright © 2023 Castaneda, Theodorescu, Rosser and Ahdoot 2023 Castaneda, Theodorescu, Rosser and Ahdoot</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3</citedby><cites>FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090444/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090444/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37064102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castaneda, Peris R</creatorcontrib><creatorcontrib>Theodorescu, Dan</creatorcontrib><creatorcontrib>Rosser, Charles J</creatorcontrib><creatorcontrib>Ahdoot, Michael</creatorcontrib><title>Identifying novel biomarkers associated with bladder cancer treatment outcomes</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms "biomarker," "bladder cancer," and the respective treatment discussed (i.e., "neoadjuvant" or "BCG"). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.</description><subject>biomarker</subject><subject>bladder cancer</subject><subject>genetic testing</subject><subject>Oncology</subject><subject>targeted therapy</subject><subject>treatment</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkctuFDEQRS0EIlHIB7BBvWQzQ_nRtnuFUARkpAg2ILGz_ChPHLrbwfYE5e_pyQxR4k1ZVXXPLekS8pbCmnM9fIh59msGjK8ppYIBf0FOGeNiNQj-6-WT_wk5r_UGlid7oMBfkxOuQAoK7JR82wScW4r3ad52c77DsXMpT7b8xlI7W2v2yTYM3d_Urjs32hCwdN7OfimtoG3Tou_yrvk8YX1DXkU7Vjw_1jPy88vnHxeXq6vvXzcXn65WXkjZVoOkvbVBhUGB4zowxyVEiiBA91F56kPgMnjsdeTog2OROmaBoudeUeRnZHPghmxvzG1Jy8X3JttkHhq5bI0tLfkRjRIyKie51k4IoL2mslcOFA9UKeHVwvp4YN3u3ISL6dyKHZ9Bn0_mdG22-c5QgAGEEAvh_ZFQ8p8d1mamVD2Oo50x76phGphgmsu9GT2s-pJrLRgffSiYfa5mn6vZ52qOuS6ad08PfFT8T5H_A1TSoCk</recordid><startdate>20230329</startdate><enddate>20230329</enddate><creator>Castaneda, Peris R</creator><creator>Theodorescu, Dan</creator><creator>Rosser, Charles J</creator><creator>Ahdoot, Michael</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230329</creationdate><title>Identifying novel biomarkers associated with bladder cancer treatment outcomes</title><author>Castaneda, Peris R ; Theodorescu, Dan ; Rosser, Charles J ; Ahdoot, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>biomarker</topic><topic>bladder cancer</topic><topic>genetic testing</topic><topic>Oncology</topic><topic>targeted therapy</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castaneda, Peris R</creatorcontrib><creatorcontrib>Theodorescu, Dan</creatorcontrib><creatorcontrib>Rosser, Charles J</creatorcontrib><creatorcontrib>Ahdoot, Michael</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castaneda, Peris R</au><au>Theodorescu, Dan</au><au>Rosser, Charles J</au><au>Ahdoot, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identifying novel biomarkers associated with bladder cancer treatment outcomes</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2023-03-29</date><risdate>2023</risdate><volume>13</volume><spage>1114203</spage><pages>1114203-</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms "biomarker," "bladder cancer," and the respective treatment discussed (i.e., "neoadjuvant" or "BCG"). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37064102</pmid><doi>10.3389/fonc.2023.1114203</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2023-03, Vol.13, p.1114203
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_746f7b6388b4401581657b073d1774c7
source PubMed Central Free
subjects biomarker
bladder cancer
genetic testing
Oncology
targeted therapy
treatment
title Identifying novel biomarkers associated with bladder cancer treatment outcomes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A42%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identifying%20novel%20biomarkers%20associated%20with%20bladder%20cancer%20treatment%20outcomes&rft.jtitle=Frontiers%20in%20oncology&rft.au=Castaneda,%20Peris%20R&rft.date=2023-03-29&rft.volume=13&rft.spage=1114203&rft.pages=1114203-&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2023.1114203&rft_dat=%3Cproquest_doaj_%3E2802428367%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c466t-9615aad7d970b38d2b360f1e04085f7c1cdd36dce58f3ecdb2f1b2a01ec3c71e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2802428367&rft_id=info:pmid/37064102&rfr_iscdi=true